Aggressive natural killer (NK) cell leukemia (ANKL) is a rare malignant lymphoproliferative disorder characterized by systemic NK cell proliferation; it is most prevalent in East Asia. 1 ANKL is highly refractory to conventional chemotherapy and has dismal outcomes.
1,2 Allo-SCT has been reported to be efficacious in treating ANKL;
3-5 the efficacy of unrelated cord blood transplantation (uCBT), however, remains unknown. We report a case of successful uCBT for refractory ANKL, with long-term CR.
A 32-year-old Japanese man was referred to our hospital for persistent fever for more than 4 months and marked hepatosplenomegaly. He had no history of mosquito-bite allergy or chronic active EBV infection. Laboratory studies revealed a large granular lymphocyte (LGL) count of 3.78 Â 10 9 /L, which accounted for 63% of the WBC count; the immunophenotype of the LGLs was CD2
The expression of NKp46, a member of the natural cytotoxicity receptor family, is strictly confined to NK cells. 6 Although NK cell neoplasms rarely stain negative for CD56, this immunophenotype indicated that these cells belonged to the NK cell lineage. A BM smear showed that LGLs accounted for 13.3% of all nucleated cells. Serological studies showed elevated anti-EBV antibody titers: viral capsid antigen-specific (VCA)-IgG, 2560 Â ; VCA-IgM, o10 Â ; early antigen-specific IgG, 320 Â and EBV nuclear antigen, 80 Â . Clonal proliferation of EBV-infected NK cells was confirmed by Southern blot analysis performed using a terminal-repeat probe from the EBV genome. Computed tomography revealed marked hepatosplenomegaly with no lymphadenopathy. Liver needle biopsy revealed scattered infiltration of lymphocytes with EBVencoded RNAs, indicating liver involvement in ANKL. The EBV-DNA load (determined by RQ-PCR) in the whole blood was 4.7 Â 10 6 copies per 10 6 cells. Based on the above-mentioned findings, the diagnosis of ANKL was confirmed.
We administered a single course of DeVIC therapy (dexamethasone, etoposide, ifosfamide and carboplatin) and a single course of SMILE therapy (dexamethasone, MTX, ifosfamide, L-asparaginase and etoposide). However, the LGL count in the peripheral blood remained high (0.32 Â 10 9 /L; 4% of the WBC count), and fever (body temperature 438 1C) recurred soon after the therapies were administered. We recognized a high risk of treatment failure and decided to perform allo-SCT. Unfortunately, no suitable donor could be identified among his family or through the Japan Marrow Donor Program; therefore, we decided to perform uCBT by using 4/6 HLA-matched female cord blood after obtaining written informed consent. The interval between diagnosis and transplant was approximately 2 months. The number of infused cells before cryopreservation was 2.45 Â 10 7 nucleated cells per kg, including 0.91 Â 10 5 CD34 þ cells per kg. Figure 1 shows the clinical course and laboratory data. Conditioning comprised etoposide 15 mg/kg on days -5 and -4 (total dose: 30 mg/kg), CY 60 mg/kg on days À3 and À2 (total dose: 120 mg/kg) and TBI with 1200 cGy in six fractions for 3 days from day À8 to day À6. For GVHD prophylaxis, we administered tacrolimus (0.02 mg/kg per day continuous infusion from day À1). G-CSF (5 mg/kg per day) was administered from day þ 1 until engraftment. Engraftment (neutrophil cell count X0.5 Â 10 9 /L) was confirmed on day þ 22. A pre-engraftment immune reaction developed on day þ 7 but was ameliorated by methylprednisolone (62.5 mg). Acute GVHD grade 3 (skin 3, liver 0, gut 1) developed on day þ 45 and was relieved by prednisolone (20 mg). After remission of acute GVHD, immunosuppressive drug treatment was rapidly tapered and discontinued from day þ 98 to enhance the GVL effect.
LGLs in the peripheral blood disappeared soon after transplantation, and no EBV DNA was detected in the peripheral blood 1 month after transplantation. Thereafter, LGLs and EBV DNA were consistently undetectable. Hepatosplenomegaly resolved within the next 3 months. FISH with probes for the X and Y chromosomes revealed no recipient-derived cells in the peripheral blood and BM. The patient sustained CR without any sign of chronic GVHD for 16 months after CBT, and his general condition is good.
The prognosis of ANKL is very poor, worse than that of extranodal NK cell lymphoma, another NK cell neoplasm. 2 The median survival time from diagnosis is approximately 58 days. 1 Refractoriness to chemotherapy may be attributed to the expression of multidrug resistance-associated P-glycoprotein. 7 Allo-SCT has been found to improve the prognosis of NK cell neoplasms. 8, 9 However, the outcome of allo-SCT for ANKL or blastic NK cell leukemia is worse than that for extranodal NK cell lymphoma. 9 In addition, no study has reported patients with ANKL who have sustained long-term CR without undergoing allo-SCT.
Teshima et al. 3 reported the first successful allo-BMT for ANKL. Since then, several cases of successful allo-SCT for ANKL have been reported, and allo-SCT was thought to be the only promising and curative approach. [3] [4] [5] Ito et al.
uCBT. However, one patient died of TRM 6 months after transplantation, and the other experienced relapse after 12 months and received a second transplant from his HLAhaploidentical mother. Hatsumi et al. 10 reported a patient who successfully underwent uCBT for ANKL during the first CR; however they mainly referred to the microscopic findings at the time of initial diagnosis and did not mention the transplant details.
Considering the refractoriness of ANKL to chemotherapy, we consider that in the present case, chemotherapy alone would not have conferred long-term survival, even though chemotherapy was partially effective. Furthermore, we speculate that the GVL effect of cord blood against ANKL contributed to the long-term CR in this patient. The findings of the present case suggest that cord blood can be an alternative stem cell source for patients with ANKL. In addition, considering that ANKL has a highly aggressive clinical course with an extremely short survival time, 1, 2 uCBT is a good treatment option because cord blood stem cells are immediately available. However, a longer followup period is required to confirm the efficacy of this treatment.
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